FindTrial
Sign In

Omalizumab (Xolair)

DRUG8 trials

Sponsors

Genentech, Inc., National Institute of Allergy and Infectious Diseases (NIAID), Scripps Clinic, National Jewish Health, Insel Gruppe AG, University Hospital Bern

Conditions

Allergic RhinitisAnaphylaxisAngioedemaAsthmaBronchospasmChronic Idiopathic UrticariaChronic Spontaneous UrticariaChronic Urticaria

Phase 1

Omalizumab to Treat Hyper-IgE (Job's) Syndrome
CompletedNCT00260702
National Institute of Allergy and Infectious Diseases (NIAID)Hyper-IgE Syndrome, Job's Syndrome
Start: 2005-11-24End: 2010-03-19Updated: 2017-07-02

Phase 2

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels
WithdrawnNCT00851370
National Jewish HealthPulmonary Disease, Chronic Obstructive
Start: 2009-01-31End: 2011-02-28Updated: 2017-03-29
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
CompletedNCT00890162
National Institute of Allergy and Infectious Diseases (NIAID)Anaphylaxis, Angioedema, Bronchospasm +1
Start: 2009-04-27End: 2019-05-31Updated: 2019-07-01
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
CompletedNCT01803763
Insel Gruppe AG, University Hospital BernChronic Idiopathic Urticaria, Chronic Spontaneous Urticaria, Chronic Urticaria
Start: 2012-09-30End: 2014-03-31Updated: 2014-04-15
Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
CompletedNCT02049294
McMaster UniversityEosinophilic Bronchitis, Steroid and/or Prednisone Dependent Asthma
Start: 2014-03-31End: 2017-09-30Updated: 2018-04-04

Phase 3

A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
CompletedNCT00314574
Genentech, Inc.Asthma
Start: 2005-12-31End: 2009-11-30Updated: 2012-02-09

Phase 4

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
CompletedNCT00096954
Genentech, Inc.Asthma
Start: 2006-02-28End: 2010-09-30Updated: 2017-06-14

Unknown Phase

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma
NCT00286416
Scripps ClinicAllergic Rhinitis, Asthma
Start: 2006-01-31End: 2008-07-31Target: 60Updated: 2006-11-07

Related Papers

No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities
Annals of Allergy Asthma & Immunology2021-01-1811 citations
Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
2019-11-2232 citations
Omalizumab in patients with severe asthma and persistent sputum eosinophilia.
2019-04-0317 citations
Tryptase loss-of-function mutations reduce tryptase expression and predict asthmatic response to anti-IgE therapy
2018-09-154 citations
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
2013-04-01657 citations